Verifi Prenatal Test就是这样一种无创检测，可对21号、18号和13号染色体的非整倍体进行筛查。对于单胎妊娠，它可提供额外的性染色体和特定微缺失的筛查。在双胎妊娠中，它提供21号、18号和13号染色体的非整倍体筛查和Y染色体缺失的筛查。结果在收到样本3-5天内报告。取决于需求，报告时间可进行调整。
|疾病||观察到的敏感性** (范围)***||观察到的特异性** (范围)***||敏感性||特异性|
|21三体||99.49% (98.66–99.53%)||99.77% (98.92–99.91%)||100%||99.76%|
|18三体||97.23% (94.20–98.15%)||99.69% (99.51–99.85%)||97.37%||99.57%|
|13三体||97.98% (95.56–98.87%)||99.84% (99.77-99.93%)||87.50%||100%|
* Illumina. verifi Prenatal Test的分析验证：针对21、18和13三体的检测性能增强，且可选择对性染色体的状态进行分类。Illumina的白皮书。20122
Click on the below to view the sensitivity and specificity data table.
|Condition||Sensitivity||95% CI||Specificity||95% CI|
NIPT performance for trisomies 21, 18, and 13 in singleton pregnancies as reported in a large, independent meta-analysis3
Data from a meta-analysis of 37 published NIPT studies between January 2011 and January 2015.
Positive predictive value (PPV) refers to the proportion of positive test results that are truly positive. PPV is based on the sensitivity and specificity of the test and the prevalence of the condition in the population being tested. Because the prevalence of autosomal trisomies (e.g. trisomy 21) increases with maternal age, so do the PPVs.
The American College of Medical Genetics (ACMG) recommends that laboratories provide patient-specific PPV when reporting positive results.4 Our test reports provide this information.
For Verifi and Verifi Plus, if a woman receives an aneuploidy detected result for trisomy 21, trisomy 18, or trisomy 13 in a singleton pregnancy, the report will include a PPV based on the test’s sensitivity and specificity for the condition, maternal age, and gestational age.
Click on the below to view a sample test report
|Chromosome 21||POSITIVE: Aneuploidy detected
Results consistent with pregnancy at increased risk for trisomy 21.
|Chromosome 18||NEGATIVE: No aneuploidy detected
Results consistent with two copies of chromosome 18.
|Chromosome 13||NEGATIVE: No aneuploidy detected
Results consistent with two copies of chromosome 13.
Because the prevalence of autosomal trisomies (eg, trisomy 21) increases with maternal age, so do the PPVs. Trisomy 21 is the most prevalent autosomal trisomy in live births. Thus, the PPVs are higher for trisomy 21 than for trisomies 18 and 13,
which are less common. The PPVs below are calculated based on age-related prevalence; the presence of other aneuploidy risk factors (e.g. ultrasound abnormalities) would likely increase the PPVs over those shown here.
Counsel the patient about the NIPT results, the likelihood of a true positive (PPV), and the recommendation for confirmatory diagnostic testing.10,11
The Verifi Prenatal Test has the lowest failure rate in the industry of 0.1%, excluding administered failed samples—that means that 99.9% of the time a result is provided13. It uses next-generation sequencing to analyze cfDNA fragments across the whole genome, which has proven advantages over other NIPT methodologies such as targeted sequencing and array-based methods. Test failure rates are substantially lower with whole-genome sequencing versus other methodologies.13-16
That’s important, and clinically relevant, because not only do test failures negatively impact patient care, they also adversely affect test metric parameters such as sensitivity, specificity, and PPV. By choosing the verifi Prenatal Test, the clinical impact of failures can be reduced.13Access PDF
We’re committed to providing laboratories and health care partners with comprehensive solutions and test options to improve human health. Published data shows, that NGS with whole-genome sequencing (WGS) is the NIPT technology of choice—when compared to targeted approaches.
With over 99.7% of NIPT samples in these studies run on Illumina NGS technology, we’re helping advance breakthrough in prenatal screening. It’s what makes the verifi Prenatal Test, with the lowest failure rate of any noninvasive prenatal test on the market, the best choice for patients.
Click on the below to view the samples run data table.
|Test (Company)||Current technology platform||Platform provider||Number of published samples|
|Illumina NGS||Ion Proton NGS||Affymetrix array|
|Bambni Test (Berry Genomics)||NGS||Illumina||3,268||0||0|
|MaterniT21 PLUS Test (Sequenom)||NGS||Illumina||293,243||0||0|
|NIFTY Test (BGI)||NGS||Illumina||168,655||0||0|
|Panorama Prenatal Screen (Natera)||NGS||Illumina||55,077||0||0|
|PrenaTest (LifeCodexx AG)||NGS||Illumina||504||0||0|
|Verifi Prenatal Test (Illumina)||NGS||Illumina||113,561||0||0|
|IONA Test (Premaltha)||NGS||Ion Proton||0||684||0|
|Harmony Prenatal Test (Arlosa)*||Array||Affymetrix||44,313||0||1,677|
A PubMed search for "cell-free, DNA, prenatal," "noninvasive prenatal testing," and "noninvasive prenatal screening" was performed on November 30, 2015. All validation and clinical studies using unique samples were included, where a current clinical NIPT provider performed sample analysis. Case studies and studies published in a language other than English were excluded. A total of 59 published studies were surveyed. Data calculations on file. Illumina, Inc. 2015. NGS = next-generation sequencing; either whole-genome or targeted.
*In 2014, Ariosa switched from sequencing to arrays for clinical samples despite limited published data on this platform.
Theoretical example of the number of invasive procedures requested due to NIPT failure and false positive rates of the assays. Failure rates include assay failures and samples rejected due to low fetal fraction. Assay failure rate for the Harmony test is based on NGS studies and may not be consistent with actual test results achieved using the array-based Harmony Test currently in use.13-19
†Affected pregnancies with a screening test failure were excluded from the number of detected T21.
The Verifi Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.